Popular Muscle-Building Supplement MK-677 Linked to Liver Toxicity
A case report reveals MK-677, a widely used growth hormone secretagogue, triggered significant liver damage in a healthy man in his 30s.
Summary
A new case report published in BMJ Case Reports documents hepatotoxicity in a healthy man in his early 30s following two months of MK-677 supplementation. MK-677, a growth hormone secretagogue, is increasingly popular in fitness and longevity communities for its ability to boost growth hormone and IGF-1 levels without injection. The patient developed transaminitis — elevated liver enzymes indicating liver inflammation — which resolved after discontinuing the supplement. While MK-677's known side effects include fluid retention, increased appetite, and muscle pain, liver toxicity has rarely been reported. This case highlights a potentially serious but underrecognized risk associated with an unregulated supplement that is widely accessible and frequently used for performance enhancement and anti-aging purposes.
Detailed Summary
MK-677 (ibutamoren) has gained substantial traction in both fitness and longevity communities as an oral growth hormone secretagogue that stimulates GH and IGF-1 release. Unlike injectable growth hormone, it is unregulated, inexpensive, and widely available — making safety signals particularly important to track.
This case report from Wayne State University and Henry Ford Health System describes an otherwise healthy man in his early 30s who developed transaminitis after consuming MK-677 for approximately two months. Transaminitis refers to elevated levels of liver enzymes (ALT/AST), a marker of hepatocellular injury or inflammation. Crucially, liver function tests normalized after the supplement was stopped, suggesting a direct causal relationship.
The clinical significance lies in the supplement's growing popularity. MK-677 is frequently marketed as a safer alternative to exogenous growth hormone for muscle gain, fat loss, and potential anti-aging benefits. Yet its regulatory status remains gray, and long-term safety data from rigorous human trials are limited. Prior reported side effects have been largely benign — edema, increased appetite, transient insulin resistance — making this hepatotoxicity case noteworthy.
The mechanism of MK-677-induced liver injury is not well characterized. Drug-induced liver injury (DILI) from performance-enhancing compounds is a recognized phenomenon, and this case adds MK-677 to the list of supplements warranting hepatic monitoring during use.
Physicians and patients using or considering MK-677 should be aware that liver toxicity, while apparently rare, is a real possibility. Baseline and periodic liver function testing may be prudent for anyone using this compound. The case also underscores the broader need for post-market surveillance of unregulated longevity and performance supplements.
Key Findings
- MK-677 use for 2 months caused clinically significant transaminitis in a healthy man in his early 30s.
- Liver enzymes returned to normal after MK-677 discontinuation, suggesting direct drug-induced hepatotoxicity.
- Hepatotoxicity from MK-677 is rarely reported, making this case a notable safety signal.
- Known MK-677 side effects (edema, appetite increase, muscle pain) do not typically include liver injury.
- The case highlights unmonitored hepatic risk in a widely used, unregulated longevity supplement.
Methodology
This is a single case report from a clinical setting, documenting one patient's adverse reaction to MK-677. Causality is inferred from the temporal relationship between supplement use and liver enzyme elevation, and the resolution of transaminitis after cessation. No controlled comparison or mechanistic investigation was conducted.
Study Limitations
A single case report provides very limited evidence and cannot establish incidence rates or confirm causality with certainty. Confounding factors such as other supplements, medications, or underlying conditions may not have been fully excluded. The hepatotoxic mechanism of MK-677 remains unexplained and requires further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.